These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 18841288

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
    Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R, Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators.
    Circulation; 2009 Jun 30; 119(25):3215-22. PubMed ID: 19528337
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
    Yong G, Rankin J, Ferguson L, Thom J, French J, Brieger D, Chew DP, Dick R, Eccleston D, Hockings B, Walters D, Whelan A, Eikelboom JW.
    Am Heart J; 2009 Jan 30; 157(1):60.e1-9. PubMed ID: 19081397
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C, Badar J, Covic L, Waxman S, Weintraub A, Jacques S, Kuliopulos A.
    Thromb Res; 2005 Jan 30; 116(1):55-66. PubMed ID: 15850609
    [Abstract] [Full Text] [Related]

  • 6. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Fu XH, Hao QQ, Jia XW, Fan WZ, Gu XS, Wu WL, Hao GZ, Li SQ, Jiang YF, Geng W.
    Chin Med J (Engl); 2008 Mar 20; 121(6):522-7. PubMed ID: 18364139
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S, Ambrosini V, Marzocchi A, Tolaro S, Petronio AS, Galassi AR, Bongo AS, Gaglione A, Bolognese L, IDEA Survey Investigators, Italian Society of Invasive Cardiology.
    Ital Heart J; 2005 Feb 20; 6(2):106-18. PubMed ID: 15819503
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
    Lepäntalo A, Virtanen KS, Heikkilä J, Wartiovaara U, Lassila R.
    Eur Heart J; 2004 Mar 20; 25(6):476-83. PubMed ID: 15039127
    [Abstract] [Full Text] [Related]

  • 12. [Optimal platelet inhibition after coronary stent implantation. Current status].
    Silber S, Hoffmeister HM, Bode C.
    Herz; 2008 Jun 20; 33(4):244-53. PubMed ID: 18581073
    [Abstract] [Full Text] [Related]

  • 13. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials.
    Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, Singh S, Khosla S.
    Can J Cardiol; 2011 Jun 20; 27(5):548-54. PubMed ID: 21871775
    [Abstract] [Full Text] [Related]

  • 14. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z, Kala P.
    Clin Ther; 2008 Jun 20; 30 Pt 2():2191-202. PubMed ID: 19281914
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.
    Abuzahra M, Pillai M, Caldera A, Hartley WB, Gonzalez R, Bobek J, Dokainish H, Lakkis N.
    Am J Cardiol; 2008 Aug 15; 102(4):401-3. PubMed ID: 18678295
    [Abstract] [Full Text] [Related]

  • 18. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R, FABOLUS PRO Investigators.
    JACC Cardiovasc Interv; 2012 Mar 15; 5(3):268-77. PubMed ID: 22440491
    [Abstract] [Full Text] [Related]

  • 19. Platelet inhibition in percutaneous coronary interventions.
    Wyss CA, Roffi M.
    Herz; 2005 May 15; 30(3):189-96. PubMed ID: 15902369
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.